Today: 16 June 2026
EOSE stock: Eos Energy slips again premarket after brutal earnings selloff and softer 2026 outlook
27 February 2026
2 mins read

EOSE stock: Eos Energy slips again premarket after brutal earnings selloff and softer 2026 outlook

New York, Feb 27, 2026, 06:49 (EST) — Premarket

• Shares slipped another 2.5% before the bell, adding to Thursday’s steep 39.4% drop.
• Eos delivered record Q4 revenue, yet set its 2026 revenue guidance under what analysts had been looking for.
• Roth Capital lowered its price target, citing execution risk following the Q4 release.

Eos Energy Enterprises shares slipped another 2.5% before the bell Friday, adding to a brutal 39.4% plunge in the previous session as investors dumped the battery maker following its latest quarterly numbers and 2026 guidance. The stock was recently quoted at $6.57. It had settled at $6.74 Thursday, with around 151 million shares changing hands. StockAnalysis

This volatility comes as Eos pushes its zinc-based energy storage systems to utilities and commercial buyers—a crowd that hasn’t hesitated to hit the stock for delays or heavy spending. These days, shares react sharply to every update. How things open Friday could signal if investors are buying the post-earnings pivot. Reuters

The core of the argument boils down to this: Can Eos actually get those booked orders out the door quickly enough to shrink its losses, or is another capital raise coming? Traders are eyeing the company’s first full-year revenue forecast, trying to decide if it’s the baseline—or just out of reach.

Eos posted its highest-ever fourth-quarter revenue at $58.0 million, with full-year sales climbing to $114.2 million, according to a regulatory filing. Even so, the company logged a net loss to shareholders of $120.5 million for the quarter and $969.6 million for the year—mostly tied to non-cash fair-value and capital-structure effects. Looking ahead, Eos rolled out a 2026 revenue target between $300 million and $400 million. That earlier “substantial doubt” over its ability to keep operating? Gone, the company said, dropping the going-concern warning. CEO Joe Mastrangelo described 2025 as a “structural turning point,” though he acknowledged revenue results fell short of what they’d hoped. SEC

Wall Street zeroed in on the shortfall between the company’s outlook and consensus numbers. Roth Capital’s Chip Moore dropped his price target down to $6 from $12, maintaining a neutral stance. “Execution risks remain high,” Moore wrote, warning the shares may continue reacting to specific events. TheFly’s figures showed consensus revenue for 2026 at $471.26 million; analysts had penciled in a fourth-quarter loss of 84 cents a share, far wider than the 24-cent loss expected. TipRanks

Eos has turned to capital markets for breathing room as it works to scale up production. The company is using convertible notes—debt instruments that may eventually convert into equity, potentially diluting current shareholders. For now, they extend debt maturities and help bolster short-term liquidity.

During the earnings call, Mastrangelo flagged capacity and factory throughput as the areas to watch next, telling analysts the Turtle Creek facility “hit its nameplate capacity” after 2025. He said putting up a new building would “change the game” for both cost and efficiency. Investing.com

The firm is leaning hard on its Indensity product architecture these days, hoping to shift investor focus away from choppy quarterly swings. Management keeps steering attention to the backlog and pipeline, but ultimately, it’s going to come down to deliveries and margin—no amount of slides will change that.

Eos goes up against big lithium-ion names and other storage players, with price cuts landing hard whenever buyers have choices. Eos sells its chemistry on safety and longer storage, but for investors, the whole thing hangs on whether the numbers at the factory add up.

But the downside is clear enough: gross losses are still big, and if production yields slip, supply costs climb, or customers struggle with financing, revenue could get delayed while cash burn keeps running high. Shares could tumble again even without a big headline—something as routine as a delayed shipment or softer margins might be enough.

Stock Market Today

  • Zip Co Limited (ASX:ZIP) Shows Potential Recovery with Inverse Head & Shoulders Breakout
    June 15, 2026, 9:57 PM EDT. Zip Co Limited (ASX:ZIP) is signaling a potential recovery through an inverse head and shoulders breakout, a technical chart pattern often indicating a trend reversal. This formation suggests improving investor sentiment and possible upward momentum for the digital payments company. However, investors should consider comprehensive financial advice before acting on this technical signal, as past patterns do not guarantee future performance.

Latest articles

Nasdaq steady in late trading as oil eases, Fed up next

Nasdaq steady in late trading as oil eases, Fed up next

16 June 2026
U.S. stocks soared Monday as falling oil prices and a preliminary U.S.-Iran deal fueled a relief rally, with the Nasdaq up 3.07%, S&P 500 up 1.65%, and Dow closing at a record high; after-hours futures dipped slightly as investors awaited Wednesday’s pivotal Federal Reserve decision and Chair Kevin Warsh’s first post-meeting press conference.
Intel stock gains after BofA upgrade, foundry business in focus

Intel Gains as Chip Shares Recover

16 June 2026
Intel surged to $127.86, topping analyst targets, as chip stocks rallied on easing inflation and AI optimism, but the stock’s gains outpace consensus expectations and recent earnings remain negative; investors now await the unconfirmed July 23 earnings report for proof that demand is driving real revenue growth.
Dave & Buster’s falls after Q1 comes up short, comps slip

Dave & Buster’s falls after Q1 comes up short, comps slip

16 June 2026
Dave & Buster’s shares plunged 4.72% to $12.32, then dropped another 11.2% after hours, after Q1 revenue, adjusted profit, and comparable-store sales all missed expectations; management’s guidance for positive sales trends and free-cash-flow remains the next key catalyst as investors weigh the company’s turnaround credibility.
GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal
Previous Story

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

CBA’s $1 Billion Mortgage Fraud Alarm: Big Banks Face New AI-Document Threat
Next Story

CBA’s $1 Billion Mortgage Fraud Alarm: Big Banks Face New AI-Document Threat

Go toTop